|
Report Date : |
15.02.2014 |
IDENTIFICATION DETAILS
|
Name : |
SHIN HWA PHARMACEUTICAL CORPORATION |
|
|
|
|
Registered Office : |
105, Seongseodong-ro, Dalseo-gu, Daegu, Korea |
|
|
|
|
Country : |
South Korea |
|
|
|
|
Date of Incorporation : |
27.08.1998 |
|
|
|
|
Com. Reg. No.: |
514-81-30977 |
|
|
|
|
Legal Form : |
Co., Ltd by shares |
|
|
|
|
Line of Business : |
Manufacture of Medicinal Chemicals and Antibiotics |
|
|
|
|
No. of Employees : |
32 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
Unknown |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2013
|
Country Name |
Previous Rating (30.06.2013) |
Current Rating (30.09.2013) |
|
South Korea |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SOUTH KOREA - ECONOMIC
OVERVIEW
South Korea over the past four decades has demonstrated incredible growth and global integration to become a high-tech industrialized economy. In the 1960s, GDP per capita was comparable with levels in the poorer countries of Africa and Asia. In 2004, South Korea joined the trillion dollar club of world economies, and is currently the world's 12th largest economy. Initially, a system of close government and business ties, including directed credit and import restrictions, made this success possible. The government promoted the import of raw materials and technology at the expense of consumer goods, and encouraged savings and investment over consumption. The Asian financial crisis of 1997-98 exposed longstanding weaknesses in South Korea's development model including high debt/equity ratios and massive short-term foreign borrowing. GDP plunged by 6.9% in 1998, and then recovered by 9% in 1999-2000. Korea adopted numerous economic reforms following the crisis, including greater openness to foreign investment and imports. Growth moderated to about 4% annually between 2003 and 2007. Korea''s export focused economy was hit hard by the 2008 global economic downturn, but quickly rebounded in subsequent years, reaching 6.3% growth in 2010. The US-South Korea Free Trade Agreement was ratified by both governments in 2011 and went into effect in March 2012. Throughout 2012 the economy experienced sluggish growth because of market slowdowns in the United States, China, and the Eurozone. The incoming administration in 2013, following the December 2012 presidential election, is likely to face the challenges of balancing heavy reliance on exports with developing domestic-oriented sectors, such as services. The South Korean economy''s long term challenges include a rapidly aging population, inflexible labor market, and heavy reliance on exports - which comprise half of GDP
|
Source
: CIA |
Basic
|
Company Name |
SHIN HWA PHARMACEUTICAL CORPORATION (Korean Company Name : “신화제약(주)”) |
|
Registered
Address |
105, Seongseodong-ro, Dalseo-gu, Daegu, Korea |
|
Building |
|
|
Zip Code |
704-833 |
|
Tel |
+82-53-581-7668 |
|
Fax |
+82-53-581-7691 |
|
E-mail |
shp@shinhwa-p.co.kr;mailshp@naver.com;docori@hanmail.net |
|
Website |
www.shinhwa-p.co.kr |
|
Trading Address |
105, Seongseodong-ro, Dalseo-gu, Daegu, Korea (Old Address System : 931-2, Woram-dong, Dalseo-gu, Daegu, Korea) |
|
Tel |
+82-53-581-7690 |
|
Fax |
+82-53-581-7691 |
|
Other Address |
|
|
Tel |
|
|
Fax |
|
|
Type |
Export/Import |
|
Industry |
Manufacture of Medicinal Chemicals and Antibiotics |
|
Main Business |
Drug, Pharmaceuticals |
|
Sub Business |
|
|
Established
(mm/dd/yyyy) |
08/27/1998 |
The Subject owns
the premises of registered HQ address.
Detailed Products
|
Activity |
Detailed
Products (UNSPSC) |
|
Sell |
Tranquilizers and antimanic and antianxiety drugs(51141900) |
|
Sell |
Drugs used for gallbladder disease(51172000) |
|
Sell |
Cough and cold and antiallergy products(51161800) |
|
Sell |
Antiulcer and related gastrointestinal GI drugs(51171900) |
|
Sell |
Antidiabetic agents and hyperglycemic agents(51181500) |
|
Sell |
Antibiotics(51101500) |
|
Sell |
Dietary supplements and nutritional therapy products(51191900) |
|
Sell |
Non narcotic analgesics and antipyretics(51142000) |
|
Buy |
Orchids plants(10161603) |
|
Buy |
Ginseng(51212021) |
|
Buy |
Shelled nuts or seeds(50101717) |
|
Buy |
Herbal drugs(51212000) |
CEO’s
|
Name |
Kim Young-Dae |
|
Address |
Suite 101-102,
359-1, Jisan-dong, Suseong-gu, Daegu, Korea |
|
Date of Birth |
10/12/1940 |
|
Title |
President
& CEO |
|
Sex |
Male |
|
Nationality |
Korean |
Profiles
|
Capital (KRW) |
200,000,000 |
|
Employees |
32 |
|
Formation |
Co., Ltd by shares Venture Business |
|
Bank Details |
Woori
Bank-Sungseo Branch |
|
Corporate
Registered No. |
170111-0138984 |
|
Business
Registered No. |
514-81-30977 |
|
Permit &
Licenses |
Int’l Trade No.: 553650 |
|
Shareholder
Position |
N/A |
|
Company
History |
08/27/1998
Incorporated as the present name 05/22/2000 Designated as a Venture Business 10/15/2004 Moved to the present HQ address from 152-4, Sangin-dong, Dalseo-gu, Daegu, Korea 05/08/2009 Designated as a Venture Business again 12/29/2009 The
Subject voluntarily recalled sold one product(Shinhwa Wisaengdan) for the
safety. |
|
|
|
Management
|
Job
Description |
Title |
Name |
Sex |
Nationality |
Inauguration
Date |
|
President & CEO |
Mr. |
Kim Young-Dae |
Male |
Korean |
03/30/1999 |
|
Director |
Mr. |
Kim Sung-Koon |
Male |
Korean |
03/30/2011 |
|
Director |
Mr. |
Kim Sang-Kyun |
Male |
Korean |
03/02/2005 |
|
Auditor |
Mr. |
Seo Kyo-Hyun |
Male |
Korean |
03/02/2005 |
The financials are
not available, and the Subject Company does not have any obligations to release
its financials to the public.
Financial Description
|
Authorized
Capital(KRW) |
5,000,000,000 |
|
Paid-Up
Capital(KRW) |
200,000,000 |
|
Total Issued
Shares |
20,000 |
Products,
Technologies, Services Description
|
Main Products
& Services |
Drug & Pharmaceuticals |
|
Detailed
Products Spec. |
|
|
Technologies
Acquired |
|
Trade Partners &
Competitors
|
Suppliers |
|
|
Customers |
|
|
Competitors |
YUHAN CHEMICAL
INC. 5BA-402, SIHWA
INDUSTRIAL COMPLEX, 678-1, SEONGGOK-DONG, DANWON-GU, ANSAN-SI, GYEONGGI-DO,
KOREA TEL:+82-31-488-5800 FAX:+82-31-499-4115 KUNWHA
PHARMACEUTICAL CO., LTD. 94,
GARAKBON-DONG, SONGPA-GU, SEOUL, KOREA TEL:+82-2-2047-7700 FAX:+82-2-430-1135 GEO-YOUNG
CORPORATION 6, MULLAEDONG
5-GA, YEONGDEUNGPO-GU, SEOUL, KOREA TEL:+82-2-3662-8222 FAX:+82-2-3141-6492 |
Sales by Region
(Activity & Markets)
Not Available.
Court Action
Not Available.
--
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.28 |
|
|
1 |
Rs.103.67 |
|
Euro |
1 |
Rs.85.18 |
INFORMATION DETAILS
|
Report Prepared
by : |
NIS |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome
financial difficulties seems comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.